Hugh Robert WATSON

Dr. Hugh Robert WATSON

Evotec ID, Lyon, Auvergne-Rhône-Alpes, France
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
STSarah R. Tritsch
Sarah R. Tritsch
LELiliana Encinales
Liliana Encinales
NPNelly Pacheco
Nelly Pacheco
ACAndres Cadena
Andres Cadena
CCCarlos Cure
Carlos Cure
Aileen ChangAileen Chang
Aileen Chang
Objective.: To determine the frequency of chronic joint pain and stiffness 3 years after infection with chikungunya virus (CHIKV) in a Latin American cohort.Methods.: A cross-sectional followup of 120 patients from an initial cohort of 500 patients who reported joint pain 2 years after infection from the Atlántico Department, Colombia. Patients were clinically diagnosed as having CHIKV during the 2014–2015 epidemic, and baseline and followup symptoms at 40 months were evaluated in serologically confirmed cases.Results.: Of the initial 500 patients enrolled in the study, 482 had serologically confirmed chikungunya infection. From this group, 123 patients reported joint pain 20 months after infection, and 54% of those patients reported continued joint pain 40 months after infection. Therefore, 1 out of every 8 people who tested serologically positive for CHIKV infection had persistent joint pain 3 years after infection. Participants who followed up in person were predominantly adult (mean ± SD age 51 ± 14 yrs) and female (86%). The most common type of pain reported in these patients at 40 months post-infection was pain with periods of relief and subsequent reoccurrence, and over 75% reported stiffness after immobility, with 39% experiencing morning stiffness.Conclusion.: To our knowledge, this is the first report to describe persistent joint pain and stiffness 40 months after viral infection. The high frequency of chronic disease highlights the need to develop prevention and treatment methods. Further studies should be conducted to understand the similarities between post-chikungunya joint pain and rheumatoid arthritis.

8 January 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
HWHugh Robert WATSON
Hugh Robert WATSON
STSarah R. Tritsch
Sarah R. Tritsch
LELiliana Encinales
Liliana Encinales
ACAndres Cadena
Andres Cadena
CCCarlos Cure
Carlos Cure
Aileen ChangAileen Chang
Aileen Chang

1 November 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MOMegan O'DRiscoll
Megan O'DRiscoll
HSHenrik Salje
Henrik Salje
Aileen ChangAileen Chang
Aileen Chang
HWHugh Robert WATSON
Hugh Robert WATSON
Arthralgia, persistent pain or stiffness of the joints, is the hallmark symptom of chronic chikungunya virus (CHIKV) disease. Associated with significant disability and reduced quality of life, arthralgia can persist for many months following CHIKV infection. Understanding the expected duration of arthralgia persistence is important for managing clinical expectations at the individual-level as well as for estimating long-term burdens on population health following a CHIKV epidemic. A review of cohort studies reporting the prevalence of arthralgia post-CHIKV infection over multiple time points was conducted. Generalized linear models were used to estimate the average rate of arthralgia resolution following CHIKV infection. Sixteen cohort studies matching the inclusion criteria were identified and included in the analysis. An average rate of arthralgia resolution of 10.85% (95% confidence interval (CI) 9.05–12.66%) per month was estimated across studies, corresponding to an expected median time to arthralgia resolution of 6.39 months (95% CI 5.48–7.66 months) and an expected arthralgia prevalence of 72.21% (95% CI 68.40–76.23%) at 3 months post-CHIKV infection. Estimates of the average rate of arthralgia resolution and the expected prevalence of arthralgia over time post-CHIKV infection were derived. These can help inform expectations regarding the long-term public health burdens associated with CHIKV epidemics.

1 January 2021 in Journal of Hepatology
Verified
Journal Article
Open access
ESElsa Solà
Elsa Solà
EPElisa Pose
Elisa Pose
DCDaniela Campion
Daniela Campion
SPSalvatore Piano
Salvatore Piano
OROlivier Roux
Olivier Roux
MPM. Pérez-Guasch
M. Pérez-Guasch
Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis.

30 November 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
LBLars Bossen
Lars Bossen
PGPere Ginès
Pere Ginès
HVHendrik Vilstrup
Hendrik Vilstrup
HWHugh Robert WATSON
Hugh Robert WATSON
PJPeter Jepsen
Peter Jepsen

25 November 2018 in Liver International
Verified
Journal Article
Closed access
PDF file
GDGitte Aarøe Dam
Gitte Aarøe Dam
HVhendrik vilstrup
hendrik vilstrup
PAPer Kragh Andersen
Per Kragh Andersen
LBLars Bossen
Lars Bossen
HWHugh Robert WATSON
Hugh Robert WATSON
PJPeter Jepsen
Peter Jepsen